Drug data last refreshed 8h ago · AI intelligence enriched 5d ago
CILOXAN is a fluoroquinolone antibiotic (ciprofloxacin hydrochloride) delivered as an ophthalmic solution for topical eye treatment. It is indicated for bacterial eye infections including conjunctivitis and corneal ulcers. The drug works by inhibiting bacterial DNA gyrase, preventing bacterial replication in ocular tissues.
As LOE approaches, the brand team is likely consolidating and preparing for generic transition; investment in lifecycle extension or new formulations may drive limited headcount growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
CILOXAN presents limited career growth opportunities given its LOE-approaching status and minimal linked job openings (0). Roles on this product are predominantly defensive, focused on market share retention and generic transition planning rather than expansion. Career development is best pursued in growth-stage products or as a stepping stone to broader portfolio management experience.
Worked on CILOXAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo